data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

My Account

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Freight
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Adagene Inc

(NASDAQ:ADAG)

$1.60

0.13[8.84%]

Last update: 4:03PM (Delayed 15-Minutes)
Get Real Time Here

$1.60

0[0.00%]

Open1.530	Close1.530
Vol / Avg.1.063K / 17.046K	Mkt Cap70.135M
Day Range1.530 - 1.530	52 Wk Range0.900 - 2.100

0

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Latest News for Adagene Stock (NASDAQ:ADAG)

Adagene Stock (NASDAQ: ADAG)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 01, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Sep 1, 2023, 6:40AM

Thursday, August 31, 2023

Adagene's Cash Balance Of $128.8M Is Expected To Support Operations Into Late 2025
Benzinga Newsdesk - Aug 31, 2023, 7:13AM
Adagene H1 EPS $(0.08) Up From $(0.87) YoY, Sales $17.30M Up From $3.92M YoY
Benzinga Newsdesk - Aug 31, 2023, 7:12AM

Wednesday, July 05, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Jul 5, 2023, 1:37PM

Thursday, May 04, 2023

Adagene Achieves $3M Milestone In Collaboration With Exelixis For Successful Nomination Of Second SAFEbody Novel Masked Antibody-Drug Conjugate
Happy Mohamed - May 4, 2023, 9:08AM

Friday, April 21, 2023

Expert Ratings for Adagene
Benzinga Insights - Apr 21, 2023, 5:01PM
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Apr 21, 2023, 6:46AM

Tuesday, April 18, 2023

Adagene Highlights Presentation Of ADG126 Data At AACR
Benzinga Newsdesk - Apr 18, 2023, 9:21AM

Wednesday, March 29, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 29, 2023, 6:24AM

Tuesday, March 28, 2023

Adagene FY22 EPS $(1.48) Beats $(1.58) Estimate, Sales $9.29M Beat $8.87M Estimate
Michael Horton - Mar 28, 2023, 4:33PM

Tuesday, March 21, 2023

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target
Benzinga Newsdesk - Mar 21, 2023, 6:15AM

Tuesday, January 24, 2023

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $5
Benzinga Newsdesk - Jan 24, 2023, 8:08AM

Monday, January 09, 2023

Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody ADG126 Up To 10 mg/kg With Repeat Cycles In Combination With Anti-PD-1 Therapy From Dose Escalation Portion Of Phase 1b/2 Trial
Benzinga Newsdesk - Jan 9, 2023, 7:35AM

Thursday, December 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 22, 2022, 8:07AM

Monday, December 19, 2022

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The Bamboo Works - Dec 19, 2022, 9:35AM

Friday, December 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Dec 16, 2022, 1:47PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM
Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Bill Haddad - Dec 16, 2022, 6:34AM

Wednesday, December 07, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk - Dec 7, 2022, 6:34AM

Tuesday, October 25, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 25, 2022, 2:22PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Oct 25, 2022, 2:21PM

Tuesday, October 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November
Benzinga Newsdesk - Oct 11, 2022, 4:05PM

Monday, September 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Charles Gross - Sep 12, 2022, 5:06AM

Friday, September 09, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7
Benzinga Newsdesk - Sep 9, 2022, 8:36AM

Tuesday, August 02, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 2, 2022, 12:44PM

Thursday, June 30, 2022

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Jun 30, 2022, 12:03PM
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Vandana Singh - Jun 30, 2022, 8:44AM
Aspen Aerogels And 28 Stocks Moving Premarket
Lisa Levin - Jun 30, 2022, 6:33AM

Wednesday, June 29, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jun 29, 2022, 5:58PM
Adagene Announces Authorization Of $10M Buyback Program
Benzinga Newsdesk - Jun 29, 2022, 4:14PM

Friday, June 17, 2022

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jun 17, 2022, 5:32PM

Thursday, June 16, 2022

71 Biggest Movers From Yesterday
Lisa Levin - Jun 16, 2022, 5:33AM

Wednesday, June 15, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Jun 15, 2022, 12:22PM

Thursday, May 26, 2022

Adagene To Present At ASCO Jun. 3-7
Bill Haddad - May 26, 2022, 5:10PM

Wednesday, May 18, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 18, 2022, 12:09PM

Tuesday, April 26, 2022

Adagene Files For Mixed Shelf Of Up To $200M
Benzinga Newsdesk - Apr 26, 2022, 4:32PM

Friday, April 08, 2022

Adagene Highlights Presentation Of Data On Its Preclinical Antibody Candidates At American Association For Cancer Research Meeting
Benzinga Newsdesk - Apr 8, 2022, 1:12PM

Thursday, March 31, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Mar 31, 2022, 2:10PM
Adagene FY21 EPS $(1.46), Up From $(2.67) YoY; Sales $10.2M, Up From $700K YoY
Bill Haddad - Mar 31, 2022, 8:34AM

Wednesday, March 16, 2022

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Vandana Singh - Mar 16, 2022, 10:00AM
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Shanthi Rexaline - Mar 16, 2022, 8:02AM
Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 SAFEbody In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
Bill Haddad - Mar 16, 2022, 7:02AM

Tuesday, March 15, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 15, 2022, 12:32PM

Friday, March 11, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 11, 2022, 12:35PM

Thursday, March 10, 2022

Chinese Stocks Down ~2-3% Thursday; Western Media Thursday Morning Highlights Chinese Stance On Russian Invasion Could Be Becoming Less Neutral, Highlights Misinformation Being Shared By Chinese State To Chinese Citizens
Benzinga Newsdesk - Mar 10, 2022, 6:59AM

Tuesday, March 08, 2022

Adagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022
Steve Krause - Mar 8, 2022, 5:36PM

Friday, March 04, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Mar 4, 2022, 12:27PM

Wednesday, March 02, 2022

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Vandana Singh - Mar 2, 2022, 9:55AM
Adagene shares were trading higher after the company announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
Benzinga Newsdesk - Mar 2, 2022, 8:54AM
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Shanthi Rexaline - Mar 2, 2022, 7:50AM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved